Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. on April 20, 2017. The report details the approval of the 2017 Short Term Incentive Plan and the grant of equity awards to executive officers by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation structures and equity grants.
Material Changes and Compensation Details
2017 Short Term Incentive Plan
The Compensation Committee approved a cash bonus plan for 2017 based on corporate performance goals. Bonus targets are defined as a percentage of base salary:
- Thomas Looby (CEO): 50% target.
- Maximilian Scheder-Bieschin (CFO), Gregory Davault (VP Global Marketing), Russell DeLonzor (VP Operations): 40% target.
- Russdon Angold (President, Ekso Labs): 30% target.
Bonuses are weighted based on three goal categories: Strategic (financing/operating expenses), Medical (commercialization/development/units sold), and Industrial (units sold). Performance exceeding targets may result in awards up to 150% or 200% of the allocated portion.
Equity Grants
On April 20, 2017, the Committee approved stock options and restricted stock units (RSUs) under the 2014 Equity Incentive Plan. All options have an exercise price of $2.85 per share.
| Executive | Stock Options | Restricted Stock Units (RSUs) |
|---|---|---|
| Thomas Looby | 107,500 | 75,000 |
| Maximilian Scheder-Bieschin | 50,000 | 37,000 |
| Russdon Angold | 15,000 | 7,000 |
| Gregory Davault | 12,500 | 11,250 |
| Russell DeLonzor | 12,500 | 11,250 |
Vesting Terms: Options vest 25% after one year, then monthly over 36 months. RSUs vest in four equal annual installments starting one year after the grant date. Unvested RSUs are forfeited upon termination unless the termination occurs without cause or for good reason within 12 months of a change of control, in which case they vest immediately.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or general outlook statements. The Compensation Committee retains discretion to adjust awards based on the Company's cash resources as of December 31, 2017, and the date of payment. A risk factor noted is the forfeiture of unvested RSUs upon termination of service, subject to change of control exceptions.
Investor Verification Checklist
- Verify the specific corporate performance metrics (Strategic, Medical, Industrial) defined by the Compensation Committee to assess bonus achievability.
- Confirm the Company's cash position as of December 31, 2017, as this may influence the final payout of cash bonuses.
- Review the full text of the employee option and restricted stock unit agreements (referenced as exhibits) for detailed terms not summarized in this report.
- Monitor future filings for the actual payout amounts and vesting schedules relative to the 2017 fiscal year results.